Get the Stockscreener App
20.10
1.98%
0.39
After Hours:
19.65
-0.45
-2.24%
Monopar Therapeutics Inc stock is traded at $20.10, with a volume of 32,527.
It is up +1.98% in the last 24 hours and up +282.86% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
See More
Previous Close:
$19.71
Open:
$19.88
24h Volume:
32,527
Relative Volume:
0.03
Market Cap:
$106.08M
Revenue:
-
Net Income/Loss:
$-7.12M
P/E Ratio:
-26.10
EPS:
-0.77
Net Cash Flow:
$-6.82M
1W Performance:
+11.11%
1M Performance:
+282.86%
6M Performance:
+3,170%
1Y Performance:
+6,405%
1-Day Range:
$19.54
$20.20
1-Week Range:
$17.52
$21.18
52-Week Range:
$0.2739
$38.50
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| MNPR | 20.10 | 106.08M | 0 | -7.12M | -6.82M | -0.77 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-21 | Initiated | ROTH Capital | Buy |
Monopar Therapeutics Inc Stock (MNPR) Latest News
(MNPR) Proactive Strategies - Stock Traders Daily
HC Wainwright Has Positive Estimate for MNPR FY2024 Earnings - MarketBeat
HC Wainwright Issues Positive Forecast for Monopar Therapeutics (NASDAQ:MNPR) Stock Price - MarketBeat
Monopar Therapeutics stock target lifted, buy rating on AstraZeneca deal By Investing.com - Investing.com UK
Monopar Therapeutics (NASDAQ:MNPR) Releases Financial Results for the Third Quarter 2024Monopar Therapeutics Inc. recently disclosed its financial results for the third quarter ending September 30, 2024, in a press release dated November 8, 2024. The - Defense World
MNPRMonopar Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
(MNPR) Investment Report - Stock Traders Daily
Monopar Therapeutics Inc Reports Q3 2024 GAAP EPS of -$0.37 and Net Loss of $1.3 Million - GuruFocus.com
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments - The Manila Times
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments - GlobeNewswire Inc.
Monopar Therapeutics Inc. (MNPR) Quarterly 10-Q Report - Quartzy
Janus Henderson Group PLC Acquires New Stake in Monopar Therapeu - GuruFocus.com
RA Capital Management, L.P. Acquires New Stake in Monopar Therap - GuruFocus.com
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock - The Manila Times
Insider Purchase: CFO Karthik Radhakrishnan Acquires Shares of M - GuruFocus.com
Monopar Therapeutics Closes $19.2 Million Stock Offering - TipRanks
Monopar Therapeutics drops 16%, prices $19M offering at $16.25 per share - MSN
(MNPR) Investment Analysis - Stock Traders Daily
Monopar Therapeutics announces public stock offering By Investing.com - Investing.com Nigeria
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock - The Manila Times
Monopar Therapeutics announces public stock offering - Investing.com
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock - The Manila Times
Monopar Therapeutics Inc. (NASDAQ:MNPR) Sees Significant Drop in Short Interest - MarketBeat
Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners are retail investors who got richer after stock soared 208% last week - Simply Wall St
Individual investors are Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners and were rewarded after market cap rose by US$40m last week - Yahoo Finance
Monopar Therapeutics Skyrockets 400% on Licensing Deal - MSN
Wilmette startup's stock soars as it buys back the drug its founder made from Big Pharma - Crain's Chicago Business
Monopar Therapeutics (NASDAQ:MNPR) Shares Gap DownHere's What Happened - MarketBeat
What's Going On With Monopar Therapeutics Shares Friday? - Benzinga
Monopar Therapeutics Secures License for Wilson Disease Treatment - Yahoo Finance
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
MNPR,NTLA,CPRI,WDC,TSLA: Top 5 Trending Stocks TodayMonopar Therapeutics (NASDAQ:MNPR), Capri Holdings (NYSE:CPRI) - Benzinga
Monopar Therapeutics Inc. has entered into an agreement to acquire worldwide license to ALXN-18 from Alexion Pharmaceuticals, Inc. - Marketscreener.com
Health Care Down Amid Mixed Drug Developments -- Health Care Roundup - MarketWatch
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.33% - MSN
Viking Therapeutics stock soars on heels of Q3 beat - Yahoo Finance
Monopar Therapeutics (NASDAQ:MNPR) Hits New 52-Week HighStill a Buy? - MarketBeat
Monopar secures global license for Wilson disease drug - Investing.com
Monopar retrieves Wilson disease candidate from AstraZeneca's scrap heap - Fierce Biotech
CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines - Yahoo Finance
Monopar Therapeutics, Energy Vault Holdings, FREYR Battery: 3 Stocks Retailers Are Most Bullish Thursday Afternoon - Barchart
Why Is Monopar Therapeutics Stock Surging Over 400% On Thursday?AstraZeneca (NASDAQ:AZN), Monopar Therapeutics (NASDAQ:MNPR) - Benzinga
Monopar Up 450%Were You On Board? - RTTNews
Monopar Therapeutics (MNPR) Shares Surge on Partnership with Ale - GuruFocus.com
Monopar (MNPR) Experiences Stock Boost After An Agreement - Stocks Telegraph
Monopar Shares Surge on AstraZeneca Licensing Deal -- Update - MarketWatch
Monopar stock soars to 52-week high, hits $8.75 - Investing.com
Monopar secures global license for Wilson disease drug By Investing.com - Investing.com South Africa
Monopar Shares Rise on AstraZeneca Licensing Deal - Marketscreener.com
Monopar stock climbs as it takes over Wilson disease drug candidate (NASDAQ:MNPR) - Seeking Alpha
Monopar Therapeutics Inc Announces Agreement with Alexion, AstraZeneca Rare Disease for Late-Stage Wilson Disease Drug Candidate - Marketscreener.com
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Monopar Therapeutics Inc Stock (MNPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cittadine Andrew | Chief Operating Officer |
Jun 20 '24 |
Buy |
0.74 |
20,508 |
15,254 |
186,132 |
| Cittadine Andrew | Chief Operating Officer |
Jun 18 '24 |
Buy |
0.86 |
12,000 |
10,320 |
165,624 |
| Cittadine Andrew | Chief Operating Officer |
Jun 14 '24 |
Buy |
0.93 |
12,000 |
11,176 |
141,624 |
| Cittadine Andrew | Chief Operating Officer |
Jun 13 '24 |
Buy |
0.91 |
12,000 |
10,920 |
129,624 |
| Cittadine Andrew | Chief Operating Officer |
Jun 17 '24 |
Buy |
0.90 |
12,000 |
10,799 |
153,624 |
| Cittadine Andrew | Chief Operating Officer |
Jun 04 '24 |
Buy |
0.78 |
12,000 |
9,360 |
117,624 |
| Cittadine Andrew | Chief Operating Officer |
Jun 03 '24 |
Buy |
0.76 |
12,000 |
9,120 |
105,624 |
| Cittadine Andrew | Chief Operating Officer |
May 31 '24 |
Buy |
0.64 |
12,000 |
7,732 |
93,624 |
| Cittadine Andrew | Chief Operating Officer |
May 30 '24 |
Buy |
0.64 |
12,000 |
7,676 |
81,624 |
| Cittadine Andrew | Chief Operating Officer |
May 29 '24 |
Buy |
0.64 |
12,000 |
7,643 |
69,624 |
1.89%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):